PHOSPHODIESTERASE-5 INHIBITORS USE IN PATIENTS WITH ERECTILE DYSFUNCTION AND CARDIOVASCULAR DISEASE IN CLINICAL PRACTICE
About 150 million men worldwide and about 50% of men aged 40-88 y.o. in outpatient practice suffer from erectile dysfunction (ED). There is a linear relation between the age and ED rate. The main reason of ED in the majority of men (about 80% of patients) is cardiovascular diseases (atherosclerosis,...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Столичная издательская компания
2016-01-01
|
| Series: | Рациональная фармакотерапия в кардиологии |
| Subjects: | |
| Online Access: | https://www.rpcardio.online/jour/article/view/969 |
| _version_ | 1797232286663442432 |
|---|---|
| author | M. N. Mamedov G. G. Sharvadze E. A. Poddubsky A. K. Ausheva |
| author_facet | M. N. Mamedov G. G. Sharvadze E. A. Poddubsky A. K. Ausheva |
| author_sort | M. N. Mamedov |
| collection | DOAJ |
| description | About 150 million men worldwide and about 50% of men aged 40-88 y.o. in outpatient practice suffer from erectile dysfunction (ED). There is a linear relation between the age and ED rate. The main reason of ED in the majority of men (about 80% of patients) is cardiovascular diseases (atherosclerosis, hypertension, diabetes mellitus), as well as certain risk factors (smoking, alcohol abuse, physical inactivity etc.). The problem of ED in cardiac outpatients and modern pharmacotherapy is discussed. The phosphodiesterase-5 (PDE5) inhibitors increase the relaxing effect of nitric oxide and increase cyclic GMP levels during sexual arousal. It results in increase of cavernosum blood flow, contributing to the physiological erection. Three PDE5 inhibitors (sildenafil, tadalafil, vardenafil) are used in clinical practice nowadays. |
| first_indexed | 2024-03-08T14:03:53Z |
| format | Article |
| id | doaj.art-454d34be46f64f96bb7b3ac1606426c9 |
| institution | Directory Open Access Journal |
| issn | 1819-6446 2225-3653 |
| language | English |
| last_indexed | 2024-04-24T15:57:52Z |
| publishDate | 2016-01-01 |
| publisher | Столичная издательская компания |
| record_format | Article |
| series | Рациональная фармакотерапия в кардиологии |
| spelling | doaj.art-454d34be46f64f96bb7b3ac1606426c92024-04-01T07:43:31ZengСтоличная издательская компанияРациональная фармакотерапия в кардиологии1819-64462225-36532016-01-016569169610.20996/1819-6446-2010-6-5-691-696968PHOSPHODIESTERASE-5 INHIBITORS USE IN PATIENTS WITH ERECTILE DYSFUNCTION AND CARDIOVASCULAR DISEASE IN CLINICAL PRACTICEM. N. Mamedov0G. G. Sharvadze1E. A. Poddubsky2A. K. Ausheva3State Research Center for Preventive MedicineState Research Center for Preventive MedicineState Research Center for Preventive MedicineState Research Center for Preventive MedicineAbout 150 million men worldwide and about 50% of men aged 40-88 y.o. in outpatient practice suffer from erectile dysfunction (ED). There is a linear relation between the age and ED rate. The main reason of ED in the majority of men (about 80% of patients) is cardiovascular diseases (atherosclerosis, hypertension, diabetes mellitus), as well as certain risk factors (smoking, alcohol abuse, physical inactivity etc.). The problem of ED in cardiac outpatients and modern pharmacotherapy is discussed. The phosphodiesterase-5 (PDE5) inhibitors increase the relaxing effect of nitric oxide and increase cyclic GMP levels during sexual arousal. It results in increase of cavernosum blood flow, contributing to the physiological erection. Three PDE5 inhibitors (sildenafil, tadalafil, vardenafil) are used in clinical practice nowadays.https://www.rpcardio.online/jour/article/view/969erectile dysfunctioncardiovascular diseasephosphodiesterase-5 inhibitors |
| spellingShingle | M. N. Mamedov G. G. Sharvadze E. A. Poddubsky A. K. Ausheva PHOSPHODIESTERASE-5 INHIBITORS USE IN PATIENTS WITH ERECTILE DYSFUNCTION AND CARDIOVASCULAR DISEASE IN CLINICAL PRACTICE Рациональная фармакотерапия в кардиологии erectile dysfunction cardiovascular disease phosphodiesterase-5 inhibitors |
| title | PHOSPHODIESTERASE-5 INHIBITORS USE IN PATIENTS WITH ERECTILE DYSFUNCTION AND CARDIOVASCULAR DISEASE IN CLINICAL PRACTICE |
| title_full | PHOSPHODIESTERASE-5 INHIBITORS USE IN PATIENTS WITH ERECTILE DYSFUNCTION AND CARDIOVASCULAR DISEASE IN CLINICAL PRACTICE |
| title_fullStr | PHOSPHODIESTERASE-5 INHIBITORS USE IN PATIENTS WITH ERECTILE DYSFUNCTION AND CARDIOVASCULAR DISEASE IN CLINICAL PRACTICE |
| title_full_unstemmed | PHOSPHODIESTERASE-5 INHIBITORS USE IN PATIENTS WITH ERECTILE DYSFUNCTION AND CARDIOVASCULAR DISEASE IN CLINICAL PRACTICE |
| title_short | PHOSPHODIESTERASE-5 INHIBITORS USE IN PATIENTS WITH ERECTILE DYSFUNCTION AND CARDIOVASCULAR DISEASE IN CLINICAL PRACTICE |
| title_sort | phosphodiesterase 5 inhibitors use in patients with erectile dysfunction and cardiovascular disease in clinical practice |
| topic | erectile dysfunction cardiovascular disease phosphodiesterase-5 inhibitors |
| url | https://www.rpcardio.online/jour/article/view/969 |
| work_keys_str_mv | AT mnmamedov phosphodiesterase5inhibitorsuseinpatientswitherectiledysfunctionandcardiovasculardiseaseinclinicalpractice AT ggsharvadze phosphodiesterase5inhibitorsuseinpatientswitherectiledysfunctionandcardiovasculardiseaseinclinicalpractice AT eapoddubsky phosphodiesterase5inhibitorsuseinpatientswitherectiledysfunctionandcardiovasculardiseaseinclinicalpractice AT akausheva phosphodiesterase5inhibitorsuseinpatientswitherectiledysfunctionandcardiovasculardiseaseinclinicalpractice |